Study Description
Screening
Study Centers
Contact/Consent
Severe Alzheimer/Dementia Study -DUS44
The purpose of this 24 week, prospective, randomized, parallel-group, double-blind, multi-center study is to compare the effects of two different doses of a Novartis investigational drug in people with severe dementia/Alzheimers. An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase:
Phase 4
Participation Duration:
The participant will be required to visit the doctor’s office 6 times over about 28 weeks.
Protocol Number:
CENA713DUS44
The next step is to see if you (or the participant) meet the
basic criteria required for participation in this clinical trial.
Please fill out the questionnaire below to see if you (or the
participant) may be suitable for the clinical trial. Your answers to
these questions are not retained by this system. You must answer the
questions below for yourself, or, you must be the legally authorized
representative of the potential participant in order to answer the
questions on their behalf. If you (or the participant) do not meet
the preliminary qualifications, you may search for other clinical
trials of interest or sign up to the Mailing List.
Answers to all questions are required to determine if you meet
the preliminary qualifications for the study.
|